The 503A compounding pharmacy space has exploded alongside GLP-1 demand. That growth has attracted legitimate, well-run pharmacies — and a significant number of operations that are cutting corners on compliance, quality, and patient safety.

If your clinic is sourcing compounded semaglutide, tirzepatide, or any other sterile compound, you need to know how to tell the difference. Here's what most providers miss.

A pharmacy can hold an active state license and still be operating outside the bounds of 503A law. Licensure is a baseline — it doesn't tell you whether the pharmacy is following USP <797> sterile compounding standards, whether their COAs are from accredited third-party labs, or whether their BUD dates are backed by actual stability data.

When you're vetting a 503A compounder, you're not just checking a box. You're evaluating a clinical partner whose practices directly affect your patients and your license.

A Certificate of Analysis is a third-party lab document confirming potency, sterility, and endotoxin testing for a specific compounded lot. Any legitimate 503A pharmacy produces these routinely — they should be included with every shipment automatically.

If a pharmacy hesitates when you ask for a COA, or provides an in-house document rather than a third-party lab report, that's a serious problem. In-house testing is not independent verification.

Under 503A, every compounded product must be dispensed pursuant to a valid patient-specific prescription. A pharmacy offering to ship bulk quantities for "office use" without a prescription basis is operating outside 503A law — and potentially under 503B requirements they may not meet.

This is one of the most common compliance violations in the current GLP-1 supply market. If a pharmacy is willing to do this for you, they're willing to do it for everyone — and that's the kind of regulatory exposure that can trigger FDA enforcement action.

Beyond-Use Dating under USP <797> is not a policy decision — it's a scientific determination based on sterility testing and, for extended BUD dates, documented stability studies. Ask any pharmacy you're evaluating: "What is the basis for your BUD dates on sterile preparations?"

A compliant pharmacy can answer this specifically. If the answer is "that's just our standard" or they can't cite the testing behind it, their BUD dates may not be defensible under a state board inspection.

Every licensed pharmacy has a Pharmacist-in-Charge (PIC) who is legally responsible for the pharmacy's operations. You should be able to speak directly with a licensed pharmacist about formulation questions, stability concerns, or drug interactions.

If the only person you can reach is a sales representative, that's a structural problem. Clinical questions require clinical answers.

The regulatory status of compounded semaglutide and tirzepatide has shifted multiple times. The FDA's shortage list determinations, bulk drug substance lists, and enforcement discretion policies have all evolved — and continue to evolve.

A pharmacy that can't clearly articulate the current regulatory basis for their GLP-1 products is either not tracking the regulatory environment or is hoping you won't ask. Neither is acceptable.

A well-run 503A pharmacy will:

• Provide third-party COAs with every shipment, without being asked
• Require a valid patient-specific prescription for every order
• Cite specific USP <797> compliance documentation and recent inspection results
• Explain their BUD date methodology and provide stability data on request
• Have a licensed pharmacist available for clinical questions
• Carry professional liability insurance and provide a certificate on request
• Ship sterile compounds with validated cold-chain packaging and temperature monitoring

If a pharmacy checks all of these boxes, you have a legitimate clinical partner. If they can't — or won't — answer these questions, you're taking on risk that belongs to them.

FDA enforcement activity in the compounding space has increased significantly. State pharmacy boards are conducting more inspections. And as the GLP-1 market matures, the pharmacies that have been cutting corners are increasingly visible to regulators.

Your clinic's compliance posture depends in part on the partners you choose. A pharmacy that gets shut down mid-supply cycle doesn't just create an operational problem — it creates a patient care problem and a potential regulatory inquiry into your sourcing practices.

Do the due diligence now. It's far less expensive than the alternative.

MedClinic Partners pre-vets every pharmacy in our network against these standards. Our provider portal gives you access to compliant 503A supply with COAs on every shipment, overnight cold-chain delivery, and a licensed pharmacist available for clinical questions. NPI verification takes under 60 seconds.